Core Viewpoint - The successful implementation of the EVO+ICL(V5) implant surgery at Liaocheng Huaxia Eye Hospital marks a significant advancement in refractive correction technology, providing a new, precise, and comfortable option for myopia patients [1][4]. Group 1: Surgery Details - The first patient for this surgery was a 21-year-old university student with complex refractive issues, including nearly 1000 degrees of myopia and over 200 degrees of astigmatism [3]. - The patient was unable to undergo laser surgery due to corneal limitations but opted for the EVO+ICL(V5) technology after researching its advantages for high myopia correction [3]. Group 2: Technological Advancements - The EVO+ICL(V5) surgery represents a technological upgrade with two key advantages: superior visual quality and enhanced correction precision [4]. - The optical design of the V5 crystal has been improved, expanding the optical zone diameter to 6.1mm, which reduces visual disturbances like glare and halos, particularly benefiting those who work at night or drive [4]. - The correction precision for moderate myopia (below 600 degrees) has improved from 50 degrees to 25 degrees, allowing for more customized solutions for patients [4]. Group 3: Surgical Process and Outcomes - The surgery was performed by Dr. Yu Ruiyun, an expert with over 10 years of experience, who completed the procedure in about ten minutes with no pain reported by the patient [6]. - Post-surgery, the patient experienced a significant improvement in vision, achieving a visual acuity of 1.0 in both eyes within two hours of the procedure [8]. - Dr. Yu emphasized that the EVO+ICL(V5) technology represents a leap in visual quality, moving from merely seeing to seeing clearly and well [9]. Group 4: Future Plans - The hospital plans to continue developing its refractive services, leveraging its expert team and quality management systems to provide advanced, high-quality, and personalized visual health solutions for various vision issues, especially for high myopia patients [9].